NeuroPace (NPCE) Analyst Targets Suggest +60% Upside Potential

Key Takeaways

• The central target of $20 is the arithmetic mean of seven verified analyst price targets reviewed for NeuroPace, Inc. (NPCE), ranging from $18 to $22.
• With shares recently trading near $12.50, reaching $20 would require a roughly 60% advance—a very large move.
• The analyst range is relatively tight ($18–$22), and ratings skew strongly bullish, but the company is not yet profitable.
• Supporting factors include high-double-digit revenue growth, a differentiated RNS (responsive neurostimulation) platform, and a pending FDA indication expansion.
• Biggest risks include persistent net losses, a stock near its 52-week low, and valuation or reimbursement headwinds in medtech.
• For more context, explore Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
• For AI-driven market scanning across thousands of tickers, explore Trending AI Robots.

Analyst Price Targets and Consensus View

NeuroPace, Inc. (NPCE) is a commercial-stage medical device company that develops the RNS System, an implantable responsive neurostimulation device for people with drug-resistant epilepsy. The central target of $20 reflects seven current individual price targets that can be attributed to specific firms: KeyBanc ($18, initiated September 2026), Wells Fargo ($19), H.C. Wainwright ($20, raised from $19 after results), J.P. Morgan ($20), Lake Street ($20), Cantor Fitzgerald ($21), and Mizuho ($22, initiated July 2026). The arithmetic mean of these targets is exactly $20.00, with a low-to-high range of $18 to $22.

Independent aggregators broadly corroborate this picture—most cite an average analyst price target near $20 to $20.50 and a consensus rating in "Strong Buy" to "Moderate Buy" territory. The narrow spread signals agreement on the company's growth trajectory even if the stock has traded well below the targets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Analysts' bullishness rests primarily on the RNS platform's differentiation and its expanding addressable market, while the $18 low reflects more caution about execution and profitability timing.

Current Market Position and Path Toward the Target

NPCE shares recently traded near $12.50, close to the low end of a 52-week range of $12.00 to $19.60. That means the $20 central target sits above even the stock's prior 52-week high, underscoring the scale of the move required. From $12.50, reaching $20 implies roughly 60% upside—a very large move that would require a meaningful re-rating, not just incremental improvement.

The company generated about $107 million in trailing-twelve-month revenue, up roughly 33% year over year, with a gross margin near 80%—an attractive profile for a medtech growth story. However, NeuroPace remains unprofitable, reporting a net loss near $19 million and EPS (earnings per share) of roughly negative $0.57. The path toward the target therefore depends on sustained revenue growth, progress toward profitability, and the market rewarding that combination with a higher valuation multiple.

What Could Support a Move Toward the Target

• Revenue momentum: High-double-digit growth reflects deeper adoption of the RNS System in the underpenetrated drug-resistant epilepsy market.
• Indication expansion: The company filed a Premarket Approval Supplement with the U.S. FDA (Food and Drug Administration) to broaden the RNS System's labeled indication to idiopathic generalized epilepsy, supported by NAUTILUS trial data showing a 77% median reduction in generalized tonic-clonic seizures.
• Analyst support: Recent initiations (KeyBanc, Mizuho) and target increases (H.C. Wainwright) suggest strengthening institutional conviction.
• High gross margin: A margin near 80% provides operating leverage as revenue scales.

What Could Prevent the Target From Being Reached

• Profitability gap: Ongoing net losses and negative EPS mean the stock lacks the earnings support that often anchors a sustained re-rating.
• Downward price trend: The stock sits near its 52-week low after a substantial decline from its May 2026 high near $19.60, indicating weak near-term investor sentiment.
• Valuation risk: With a price-to-sales ratio around 4 and elevated forward multiples, growth must continue to justify the valuation.
• Execution and regulatory risk: FDA review of the indication expansion, reimbursement dynamics, and commercialization costs could all temper momentum.

Technical Levels and Market Structure

The shares have broken down from a 52-week high near $19.60 in May 2026 to the $12 area, a decline of roughly 35%. The $12.00 level, tested in early November, now acts as a key support zone. On the upside, the $19.60 prior high represents the most significant resistance level between the current price and the $20 target—meaning the stock must first reclaim its former high before the analyst-derived objective comes into view. The $20 level itself aligns closely with both the calculated mean and a round psychological threshold.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms vary in their assumptions. Because the specific time frames behind each target are not always disclosed, investors should treat the $20 figure as directional rather than time-bound. Key items to watch include the next quarterly earnings report and updated guidance, any progress on the FDA indication expansion, revenue growth and operating-loss trends, gross margin durability, and any analyst rating or target revisions. Broader medtech sentiment and interest-rate conditions can also influence the multiple investors are willing to pay for unprofitable growth. From what I see, monitoring these elements closely will be essential.

Final Assessment

Can NeuroPace reach $20? The question is not a trivial one, because the $20 central target—the average of seven analyst price targets ranging from $18 to $22—requires a roughly 60% advance from a stock trading near $12.50, below its own 52-week high. The strongest supports are 33% revenue growth, a differentiated RNS platform, near-80% gross margins, and a pending indication expansion that could widen the addressable market. The principal obstacles are persistent losses, a steep recent drawdown, and the need to reclaim the $19.60 prior high. The narrow analyst range reflects broad agreement on the growth thesis, but the magnitude of the move makes the target demanding rather than assured. Investors should monitor earnings, FDA developments, and profitability progress rather than treat the $20 figure as a guaranteed outcome.

Exploring AI Daily Buy/Sell Signals

In my analysis, I often turn to Tickeron's AI Daily Buy/Sell Signals for a systematic view of changing conditions. This tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. It helps me discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning, complementing fundamental research with a data-driven perspective on daily momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume